{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.1","upperLimit":"68.1","value":"58.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"}],"units":"Participants"}],"description":"Duration of response is defined as the time from first observation of response until progression of disease or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only results for pazopanib are given because there were not enough placebo responders.","reportingStatus":"POSTED","timeFrame":"Time from response until progression (up to 2 years)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"weeks"}